US 11,865,133 B2
Pharmaceutical composition comprising organoid and anti-inflammatory agent for preventing or treating inflammatory bowel disease
Jun-Hyeok Park, Seongnam-si (KR); Hyemi Jeon, Seongnam-si (KR); Taegyu Lim, Seongnam-si (KR); Hayoung Song, Seongnam-si (KR); Han Kyung Kim, Seongnam-si (KR); Hyokyung Lee, Seongnam-si (KR); and Ji Hye Tak, Seongnam-si (KR)
Assigned to ORGANOIDSCIENCES LTD., Daejeon (KR)
Appl. No. 18/013,770
Filed by ORGANOIDSCIENCES LTD., Daejeon (KR)
PCT Filed Sep. 16, 2022, PCT No. PCT/KR2022/013907
§ 371(c)(1), (2) Date Dec. 29, 2022,
PCT Pub. No. WO2023/043272, PCT Pub. Date Mar. 23, 2023.
Claims priority of application No. 10-2021-0124721 (KR), filed on Sep. 17, 2021.
Prior Publication US 2023/0210886 A1, Jul. 6, 2023
Int. Cl. A61K 31/7125 (2006.01); A61P 1/04 (2006.01); A61K 31/713 (2006.01)
CPC A61K 31/7125 (2013.01) [A61K 31/713 (2013.01); A61P 1/04 (2018.01)] 7 Claims
 
1. A pharmaceutical composition for preventing or treating inflammatory bowel disease, comprising an intestinal organoid and a TNFα inhibitor,
wherein the inflammatory bowel disease is one or more selected from the group consisting of ischemic colitis, intestinal Behcet's disease, Crohn's disease, ulcerative colitis and ulcerative proctitis.